Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PROTONIX® Highlights (pantoprazole sodium)


These highlights do not include all the information needed to use PROTONIX safely and effectively. See full prescribing information for PROTONIX.

PROTONIX (pantoprazole sodium) delayed-release tablets, for oral use
PROTONIX (pantoprazole sodium) for delayed-release oral suspension
Initial U.S. approval: 2000


PROTONIX is a proton pump inhibitor (PPI) indicated for the following:

Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) (1.1)
Maintenance of Healing of Erosive Esophagitis (1.2)
Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome (1.3)


Controlled studies did not extend beyond 12 months

Short-Term Treatment of Erosive Esophagitis Associated With GERD (2.1)


40 mg

Once Daily for up to 8 wks

  Children (5 years and older)

    ≥ 15 kg to < 40 kg

20 mg

Once Daily for up to 8 wks

    ≥ 40 kg

40 mg

Maintenance of Healing of Erosive Esophagitis (2.1)


40 mg

Once Daily*

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (2.1)


40 mg

Twice Daily

See full prescribing information for administration instructions


Delayed-Release Tablets: 20 mg and 40 mg pantoprazole (3)
For Delayed-Release Oral Suspension: 40 mg pantoprazole (3)


Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles (4)
Patients receiving rilpivirine-containing products (4,7)


Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy. Consider additional follow-up and diagnostic testing. (5.1)
Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients. (5.2)
Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with increased risk of Clostridium difficile-associated diarrhea. (5.3)
Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (5.4)
Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (5.5)
Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue PROTONIX and refer to specialist for evaluation. (5.6)
Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin. (5.7)
Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs. (5.8)
Fundic Gland Polyps: Risk increases with long-term use, especially beyond one year. Use the shortest duration of therapy. (5.10)


Most common adverse reactions are:

For adult use (>2%): headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. (6.1)
For pediatric use (>4%): URI, headache, fever, diarrhea, vomiting, rash, and abdominal pain. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or


See full prescribing information for a list of clinically important drug interactions (7)


Pregnancy: Based on animal data, may cause fetal harm. (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 6/2023

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event